Skip to main content

Journal of Cancer Research and Clinical Oncology

Ausgabe 12/2019

Inhalt (23 Artikel)

Review – Cancer Research

Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer

Chunyan Li, Lin Zhang, Guangping Meng, Qi Wang, Xuejiao Lv, Jie Zhang, Junyao Li

Open Access Review – Cancer Research

Correlations between microsatellite instability and the biological behaviour of tumours

Guang Yang, Ru-yi Zheng, Zai-shun Jin

Open Access Original Article – Cancer Research

Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer

Ying Wang, Yanxia Liu, Lina Zhang, Li Tong, Yuan Gao, Fanbin Hu, Peter Ping Lin, Baolan Li, Tongmei Zhang

Original Article – Cancer Research

Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma

Xiaolin Peng, Yao Liu, Shan Zhu, Xin Peng, Hui Li, Wenhui Jiao, Peng Lin, Zhe Zhang, Yuling Qiu, Meihua Jin, Ran Wang, Dexin Kong

Original Article – Cancer Research

Are shape morphologies associated with survival? A potential shape-based biomarker predicting survival in lung cancer

Maliazurina Saad, Ik Hyun Lee, Tae-Sun Choi

Original Article – Cancer Research

Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo

Qianqian Jiang, Yue Yuan, Yi Gong, Xinmei Luo, Xiaolan Su, Xueting Hu, Wen Zhu

Original Article – Cancer Research

Differential expression of p52 and RelB proteins in the metastatic and non-metastatic groups of uveal melanoma with patient outcome

Mithalesh Kumar Singh, Lata Singh, Kunzang Chosdol, Neelam Pushker, Neeru Saini, Rachna Meel, Sameer Bakhshi, Seema Sen, Seema Kashyap

Open Access Original Article – Cancer Research

Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015–2018

Lidija Stevanovic, Matthias Choschzick, Linda Moskovszky, Zsuzsanna Varga

Open Access Original Article – Cancer Research

Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis

Xialing Huang, Liling Long, Jieqin Wei, Yajuan Li, Yuwei Xia, Panli Zuo, Xiangfei Chai

Review – Clinical Oncology

Prognostic value and clinicopathological roles of phenotypes of tumour-associated macrophages in colorectal cancer

Yamei Zhao, Xiaoxu Ge, Xiaoming Xu, Shaojun Yu, Jian Wang, Lifeng Sun

Review – Clinical Oncology

Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors

Ning Zhu, Shanshan Weng, Juan Wang, Jiaqi Chen, Linzhen Yu, Xuefeng Fang, Ying Yuan

Review – Clinical Oncology

A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis

Josias Bastian Grogg, Kym Schneider, Peter-Karl Bode, Marian Severin Wettstein, Benedikt Kranzbühler, Daniel Eberli, Tullio Sulser, Joerg Beyer, Thomas Hermanns, Christian Daniel Fankhauser

Original Article – Clinical Oncology

Increased risk for cancer after stroke at a young age: etiological relevance or incidental finding?

Christian Tanislav, Charles Christian Adarkwah, Louis Jakob, Karel Kostev

Original Article – Clinical Oncology

Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas

Frank Kroschinsky, Denise Röllig, Barbara Riemer, Michael Kramer, Rainer Ordemann, Johannes Schetelig, Martin Bornhäuser, Gerhard Ehninger, Mathias Hänel

Original Article – Clinical Oncology

ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression

Maria-Alexandra Papadimitriou, Margaritis Avgeris, Panagiotis K. Levis, Theodoros Tokas, Konstantinos Stravodimos, Andreas Scorilas

Original Article – Clinical Oncology

The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine

Cai Xiu, Xiao Li, Lingyun Wu, Feng Xu, Qi He, Zheng Zhang, Dong Wu, Luxi Song, Jiying Su, Liyu Zhou, Youshan Zhao, Ying Tao, Chunkang Chang

Open Access Original Article – Clinical Oncology

Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer

H. Vihervuori, T. A. Autere, H. Repo, S. Kurki, L. Kallio, M. M. Lintunen, K. Talvinen, P. Kronqvist

Original Article – Clinical Oncology

The effectiveness of Wilms tumor screening in Beckwith–Wiedemann spectrum

Alessandro Mussa, Kelly A. Duffy, Diana Carli, Jessica R. Griff, Riccardo Fagiano, Jonida Kupa, Garrett M. Brodeur, Giovanni Battista Ferrero, Jennifer M. Kalish

Original Article – Clinical Oncology

“Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation”

Neval E. Wareham, Qiuju Li, Henrik Sengeløv, Caspar Da Cunha-Bang, Finn Gustafsson, Carsten Heilmann, Michael Perch, Allan Rasmussen, Søren Schwartz Sørensen, Amanda Mocroft, Jens D. Lundgren

ACKNOWLEDGEMENT TO REVIEWERS

Reviewer Acknowledgements 2019

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.